{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T07:46:28Z","timestamp":1793605588505,"version":"4.5.0"},"reference-count":144,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s13555-025-01511-1","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T06:12:20Z","timestamp":1755151940000},"page":"2765-2801","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Skin-Directed Therapies in Mycosis Fungoides: An Update"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5298-6479","authenticated-orcid":false,"given":"Maciej","family":"Tota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"\u0141yko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Misi\u0105g","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"\u0141acwik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Laska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karol","family":"Bili\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julita","family":"Kulbacka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Jankowska-Konsur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"1511_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1093\/ANNONC\/MDY133","volume":"29","author":"R Willemze","year":"2018","unstructured":"Willemze R, Hodak E, Zinzani PL, et al. Primary cutaneous lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:30\u201340. https:\/\/doi.org\/10.1093\/ANNONC\/MDY133.","journal-title":"Ann Oncol"},{"key":"1511_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/S41572-021-00296-9","author":"R Dummer","year":"2021","unstructured":"Dummer R, Vermeer MH, Scarisbrick JJ, et al. Cutaneous T\u00a0cell lymphoma. Nat Rev Dis Primers. 2021. https:\/\/doi.org\/10.1038\/S41572-021-00296-9.","journal-title":"Nat Rev Dis Primers"},{"key":"1511_CR3","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1111\/BJD.19829","volume":"184","author":"M Vermeer","year":"2021","unstructured":"Vermeer M. Epidemiology of cutaneous lymphoma. Br J Dermatol. 2021;184:993\u20134. https:\/\/doi.org\/10.1111\/BJD.19829.","journal-title":"Br J Dermatol"},{"key":"1511_CR4","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1001\/JAMAONCOL.2022.3236","volume":"8","author":"ZR Cai","year":"2022","unstructured":"Cai ZR, Chen ML, Weinstock MA, et al. Incidence trends of primary cutaneous T-cell lymphoma in the US from 2000 to 2018: a SEER population data analysis. JAMA Oncol. 2022;8:1690\u20132. https:\/\/doi.org\/10.1001\/JAMAONCOL.2022.3236.","journal-title":"JAMA Oncol"},{"key":"1511_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/J.LPM.2022.104108","author":"G Dobos","year":"2022","unstructured":"Dobos G, Miladi M, Michel L, et al. Recent advances on cutaneous lymphoma epidemiology. Presse Med. 2022. https:\/\/doi.org\/10.1016\/J.LPM.2022.104108.","journal-title":"Presse Med"},{"key":"1511_CR6","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/BLOOD-2018-11-881268","volume":"133","author":"R Willemze","year":"2019","unstructured":"Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133:1703\u201314. https:\/\/doi.org\/10.1182\/BLOOD-2018-11-881268.","journal-title":"Blood"},{"key":"1511_CR7","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1175799","author":"IV Litvinov","year":"2016","unstructured":"Litvinov IV, Shtreis A, Kobayashi K, et al. Investigating potential exogenous tumor initiating and promoting factors for cutaneous T-cell lymphomas (CTCL), a rare skin malignancy. Oncoimmunology. 2016. https:\/\/doi.org\/10.1080\/2162402X.2016.1175799.","journal-title":"Oncoimmunology"},{"key":"1511_CR8","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/S00281-016-0594-9","volume":"39","author":"T Krejsgaard","year":"2017","unstructured":"Krejsgaard T, Lindahl LM, Mongan NP, et al. Malignant inflammation in cutaneous T-cell lymphoma\u2014a hostile takeover. Semin Immunopathol. 2017;39:269. https:\/\/doi.org\/10.1007\/S00281-016-0594-9.","journal-title":"Semin Immunopathol"},{"key":"1511_CR9","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1038\/S41590-024-02018-1","volume":"25","author":"R Li","year":"2024","unstructured":"Li R, Strobl J, Poyner EFM, et al. Cutaneous T\u00a0cell lymphoma atlas reveals malignant TH2 cells supported by a B\u00a0cell-rich tumor microenvironment. Nat Immunol. 2024;25:2320\u201330. https:\/\/doi.org\/10.1038\/S41590-024-02018-1.","journal-title":"Nat Immunol"},{"key":"1511_CR10","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1182\/BLOOD-2009-11-251926","volume":"116","author":"JJ Campbell","year":"2010","unstructured":"Campbell JJ, Clark RA, Watanabe R, Kupper TS. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood. 2010;116:767\u201371. https:\/\/doi.org\/10.1182\/BLOOD-2009-11-251926.","journal-title":"Blood"},{"key":"1511_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/J.EJCA.2023.113343","author":"J Latzka","year":"2023","unstructured":"Latzka J, Assaf C, Bagot M, et al. EORTC consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome - update 2023. Eur J Cancer. 2023. https:\/\/doi.org\/10.1016\/J.EJCA.2023.113343.","journal-title":"Eur J Cancer"},{"key":"1511_CR12","doi-asserted-by":"publisher","first-page":"223.e1","DOI":"10.1016\/J.JAAD.2013.08.033","volume":"70","author":"SI Jawed","year":"2014","unstructured":"Jawed SI, Myskowski PL, Horwitz S, et al. Primary cutaneous T-cell lymphoma (mycosis fungoides and S\u00e9zary syndrome): Part II. prognosis, management, and future directions. J Am Acad Dermatol. 2014;70:223.e1-223.e17. https:\/\/doi.org\/10.1016\/J.JAAD.2013.08.033.","journal-title":"J Am Acad Dermatol"},{"key":"1511_CR13","doi-asserted-by":"publisher","first-page":"371","DOI":"10.4103\/0378-6323.178903","volume":"82","author":"AB Mehta","year":"2016","unstructured":"Mehta AB, Nadkarni NJ, Patil SP, et al. Topical corticosteroids in dermatology. Indian J Dermatol Venereol Leprol. 2016;82:371. https:\/\/doi.org\/10.4103\/0378-6323.178903.","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"1511_CR14","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/J.1396-0296.2003.01639.X","volume":"16","author":"HS Zackheim","year":"2003","unstructured":"Zackheim HS. Treatment of patch-stage mycosis fungoides with topical corticosteroids. Dermatol Ther. 2003;16:283\u20137. https:\/\/doi.org\/10.1111\/J.1396-0296.2003.01639.X.","journal-title":"Dermatol Ther"},{"key":"1511_CR15","doi-asserted-by":"crossref","unstructured":"Farber EM, Cox AJ, Steinberg J, McClintock RP. Therapy of mycosis fungoides with topically applied fluocinolone acetonide under occlusive dressing. Cancer. 1966;19(2):237\u201345.","DOI":"10.1002\/1097-0142(196602)19:2<237::AID-CNCR2820190216>3.0.CO;2-P"},{"key":"1511_CR16","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/J.JAAD.2020.05.043","volume":"84","author":"S Kartan","year":"2021","unstructured":"Kartan S, Shalabi D, O\u2019Donnell M, et al. Response to topical corticosteroid monotherapy in mycosis fungoides. J Am Acad Dermatol. 2021;84:615\u201323. https:\/\/doi.org\/10.1016\/J.JAAD.2020.05.043.","journal-title":"J Am Acad Dermatol"},{"key":"1511_CR17","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/BJD.19252","volume":"184","author":"P Quaglino","year":"2021","unstructured":"Quaglino P, Prince HM, Cowan R, et al. Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Study (PROCLIPI study). Br J Dermatol. 2021;184:722. https:\/\/doi.org\/10.1111\/BJD.19252.","journal-title":"Br J Dermatol"},{"key":"1511_CR18","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1001\/ARCHDERM.134.8.949","volume":"134","author":"HS Zackheim","year":"1998","unstructured":"Zackheim HS, Kashani-Sabet M, Amin S. Topical corticosteroids for mycosis fungoides: experience in 79 patients. Arch Dermatol. 1998;134:949\u201354. https:\/\/doi.org\/10.1001\/ARCHDERM.134.8.949.","journal-title":"Arch Dermatol"},{"key":"1511_CR19","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/J.JDCR.2020.05.031","volume":"6","author":"ES Gilmore","year":"2020","unstructured":"Gilmore ES, Alexander-Savino CV, Chung CG, Poligone B. Evaluation and management of patients with early-stage mycosis fungoides who interrupt or discontinue topical mechlorethamine gel because of dermatitis. JAAD Case Rep. 2020;6:878\u201381. https:\/\/doi.org\/10.1016\/J.JDCR.2020.05.031.","journal-title":"JAAD Case Rep"},{"key":"1511_CR20","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1001\/ARCHDERM.141.9.1117","volume":"141","author":"J De Quatrebarbes","year":"2005","unstructured":"De Quatrebarbes J, Est\u00e8ve E, Bagot M, et al. Treatment of early-stage mycosis fungoides with twice-weekly applications of mechlorethamine and topical corticosteroids: a prospective study. Arch Dermatol. 2005;141:1117\u201320. https:\/\/doi.org\/10.1001\/ARCHDERM.141.9.1117.","journal-title":"Arch Dermatol"},{"key":"1511_CR21","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1080\/09546634.2017.1309349","volume":"28","author":"S Khalil","year":"2017","unstructured":"Khalil S, Bardawil T, Stephan C, et al. Retinoids: a journey from the molecular structures and mechanisms of action to clinical uses in dermatology and adverse effects. J Dermatolog Treat. 2017;28:684\u201396. https:\/\/doi.org\/10.1080\/09546634.2017.1309349.","journal-title":"J Dermatolog Treat"},{"key":"1511_CR22","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/BJD.12042","volume":"168","author":"JJ Scarisbrick","year":"2013","unstructured":"Scarisbrick JJ, Morris S, Azurdia R, et al. U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. Br J Dermatol. 2013;168:192\u2013200. https:\/\/doi.org\/10.1111\/BJD.12042.","journal-title":"Br J Dermatol"},{"key":"1511_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2019.00907","volume":"9","author":"K Tanita","year":"2019","unstructured":"Tanita K, Fujimura T, Sato Y, et al. Bexarotene reduces production of CCL22 from tumor-associated macrophages in cutaneous T-cell lymphoma. Front Oncol. 2019;9:468903. https:\/\/doi.org\/10.3389\/FONC.2019.00907.","journal-title":"Front Oncol"},{"key":"1511_CR24","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/S11899-023-00692-W","volume":"18","author":"DE Luna","year":"2023","unstructured":"Luna DE, Shinohara MM. New molecular and biological markers in cutaneous T\u00a0cell lymphoma: therapeutic implications. Curr Hematol Malig Rep. 2023;18:83\u20138. https:\/\/doi.org\/10.1007\/S11899-023-00692-W.","journal-title":"Curr Hematol Malig Rep"},{"key":"1511_CR25","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/J.1365-2133.2008.08931.X","volume":"160","author":"N Nieto-Rementer\u00eda","year":"2009","unstructured":"Nieto-Rementer\u00eda N, P\u00e9rez-Yarza G, Boyano MD, et al. Bexarotene activates the p53\/p73 pathway in human cutaneous T-cell lymphoma. Br J Dermatol. 2009;160:519\u201326. https:\/\/doi.org\/10.1111\/J.1365-2133.2008.08931.X.","journal-title":"Br J Dermatol"},{"key":"1511_CR26","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1111\/J.1365-2133.2009.09037.X","volume":"160","author":"RA Abbott","year":"2009","unstructured":"Abbott RA, Whittaker SJ, Morris SL, et al. Bexarotene therapy for mycosis fungoides and S\u00e9zary syndrome. Br J Dermatol. 2009;160:1299\u2013307. https:\/\/doi.org\/10.1111\/J.1365-2133.2009.09037.X.","journal-title":"Br J Dermatol"},{"key":"1511_CR27","unstructured":"Zhang C, Hazarika P, Ni X, Weidner DA, Duvic M. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells. Clin Cancer Res. 2002;8(5):1234\u201340."},{"key":"1511_CR28","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1001\/ARCHPEDI.161.4.356","volume":"141","author":"JB Budgin","year":"2005","unstructured":"Budgin JB, Richardson SK, Newton SB, et al. Biological effects of bexarotene in cutaneous T-cell lymphoma. Arch Dermatol. 2005;141:315\u201320. https:\/\/doi.org\/10.1001\/ARCHPEDI.161.4.356.","journal-title":"Arch Dermatol"},{"key":"1511_CR29","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1038\/JID.2015.122","volume":"135","author":"L Wang","year":"2015","unstructured":"Wang L, Demarco SS, Chen J, et al. Retinoids bias integrin expression and function in cutaneous T-cell lymphoma. J Invest Dermatol. 2015;135:2102\u20138. https:\/\/doi.org\/10.1038\/JID.2015.122.","journal-title":"J Invest Dermatol"},{"key":"1511_CR30","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1002\/AJH.20952","volume":"82","author":"SK Richardson","year":"2007","unstructured":"Richardson SK, Newton SB, Bach TL, et al. Bexarotene blunts malignant T-cell chemotaxis in Sezary syndrome: reduction of chemokine receptor\u00a04-positive lymphocytes and decreased chemotaxis to thymus and activation-regulated chemokine. Am J Hematol. 2007;82:792\u20137. https:\/\/doi.org\/10.1002\/AJH.20952.","journal-title":"Am J Hematol"},{"key":"1511_CR31","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/HON.2850","volume":"39","author":"W Kempf","year":"2021","unstructured":"Kempf W, Mitteldorf C. Cutaneous T-cell lymphomas\u2014an update 2021. Hematol Oncol. 2021;39:46\u201351. https:\/\/doi.org\/10.1002\/HON.2850.","journal-title":"Hematol Oncol"},{"key":"1511_CR32","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/J.JDIN.2021.01.002","volume":"3","author":"E Wennberg","year":"2021","unstructured":"Wennberg E, Richards PQ, Bain PA, et al. Topical treatments for early-stage mycosis fungoides using grading recommendations assessment, development and evaluation (GRADE) criteria: a systematic review. JAAD Int. 2021;3:26\u201341. https:\/\/doi.org\/10.1016\/J.JDIN.2021.01.002.","journal-title":"JAAD Int"},{"key":"1511_CR33","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.3390\/CANCERS15102849\/S1","volume":"15","author":"E Michielon","year":"2023","unstructured":"Michielon E, L\u00f3pez Gonz\u00e1lez M, Stolk DA, et al. A reconstructed human melanoma-in-skin model to study immune modulatory and angiogenic mechanisms facilitating initial melanoma growth and invasion. Cancers (Basel). 2023;15:2849. https:\/\/doi.org\/10.3390\/CANCERS15102849\/S1.","journal-title":"Cancers (Basel)"},{"key":"1511_CR34","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S0190-9622(03)01475-0","volume":"49","author":"P Heald","year":"2003","unstructured":"Heald P, Mehlmauer M, Martin AG, et al. Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase\u00a0III clinical trial. J Am Acad Dermatol. 2003;49:801\u201315. https:\/\/doi.org\/10.1016\/S0190-9622(03)01475-0.","journal-title":"J Am Acad Dermatol"},{"key":"1511_CR35","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/J.JAAD.2003.09.005","volume":"50","author":"N Apisarnthanarax","year":"2004","unstructured":"Apisarnthanarax N, Talpur R, Ward S, et al. Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot study. J Am Acad Dermatol. 2004;50:600\u20137. https:\/\/doi.org\/10.1016\/J.JAAD.2003.09.005.","journal-title":"J Am Acad Dermatol"},{"key":"1511_CR36","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1111\/J.1468-3083.2006.01635.X","volume":"20","author":"G G\u00f6kdemir","year":"2006","unstructured":"G\u00f6kdemir G, Barutcuo\u01e7lu D, Sakiz D, K\u00f6\u015fl\u00fct A. Narrowband UVB phototherapy for early-stage mycosis fungoides: evaluation of clinical and histopathological changes. J Eur Acad Dermatol Venereol. 2006;20:804\u20139. https:\/\/doi.org\/10.1111\/J.1468-3083.2006.01635.X.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1511_CR37","doi-asserted-by":"publisher","first-page":"41","DOI":"10.4274\/TJD.GALENOS.2024.60362","volume":"19","author":"H \u015eanl\u0131","year":"2025","unstructured":"\u015eanl\u0131 H, Mart HME, \u015eanl\u0131 H, Mart HME. Treatment algorithms for mycosis fungoides and S\u00e9zary syndrome. Turk J Dermatol. 2025;19:41\u201360. https:\/\/doi.org\/10.4274\/TJD.GALENOS.2024.60362.","journal-title":"Turk J Dermatol"},{"key":"1511_CR38","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/J.JAAD.2015.09.033","volume":"74","author":"EA Olsen","year":"2016","unstructured":"Olsen EA, Hodak E, Anderson T, et al. Guidelines for phototherapy of mycosis fungoides and S\u00e9zary syndrome: a consensus statement of the United States Cutaneous Lymphoma Consortium. J Am Acad Dermatol. 2016;74:27\u201358. https:\/\/doi.org\/10.1016\/J.JAAD.2015.09.033.","journal-title":"J Am Acad Dermatol"},{"key":"1511_CR39","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1001\/JAMADERMATOL.2018.5204","volume":"155","author":"K Phan","year":"2019","unstructured":"Phan K, Ramachandran V, Fassihi H, Sebaratnam DF. Comparison of narrowband UV-B with psoralen\u2013UV-A phototherapy for patients with early-stage mycosis fungoides: a systematic review and meta-analysis. JAMA Dermatol. 2019;155:335\u201341. https:\/\/doi.org\/10.1001\/JAMADERMATOL.2018.5204.","journal-title":"JAMA Dermatol"},{"key":"1511_CR40","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1001\/JAMADERMATOL.2018.5905","volume":"155","author":"P Vieyra-Garcia","year":"2019","unstructured":"Vieyra-Garcia P, Fink-Puches R, Porkert S, et al. Evaluation of low-dose, low-frequency oral psoralen\u2013UV-A treatment with or without maintenance on early-stage mycosis fungoides: a randomized clinical trial. JAMA Dermatol. 2019;155:538\u201347. https:\/\/doi.org\/10.1001\/JAMADERMATOL.2018.5905.","journal-title":"JAMA Dermatol"},{"key":"1511_CR41","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/BJD.15302","volume":"177","author":"V Grandi","year":"2017","unstructured":"Grandi V, Delfino C, Pileri A, Pimpinelli N. Maintenance phase in psoralen\u2013ultraviolet A phototherapy of early-stage mycosis fungoides. A critically appraised topic. Br J Dermatol. 2017;177:406\u201310. https:\/\/doi.org\/10.1111\/BJD.15302.","journal-title":"Br J Dermatol"},{"key":"1511_CR42","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/PHPP.12302","volume":"33","author":"W Liszewski","year":"2017","unstructured":"Liszewski W, Naym DG, Biskup E, Gniadecki R. Psoralen with ultraviolet A-induced apoptosis of cutaneous lymphoma cell lines is augmented by type\u00a0I interferons via the JAK1\u2013STAT1 pathway. Photodermatol Photoimmunol Photomed. 2017;33:164\u201371. https:\/\/doi.org\/10.1111\/PHPP.12302.","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"1511_CR43","doi-asserted-by":"publisher","first-page":"48391","DOI":"10.18632\/ONCOTARGET.10268","volume":"7","author":"T Wei","year":"2016","unstructured":"Wei T, Biskup E, Gjerdrum LMR, et al. Ubiquitin-specific protease 2 decreases p53-dependent apoptosis in cutaneous T-cell lymphoma. Oncotarget. 2016;7:48391\u2013400. https:\/\/doi.org\/10.18632\/ONCOTARGET.10268.","journal-title":"Oncotarget"},{"key":"1511_CR44","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1001\/ARCHDERM.136.6.748","volume":"136","author":"C Clark","year":"2000","unstructured":"Clark C, Dawe RS, Evans AT, et al. Narrowband TL-01 phototherapy for patch-stage mycosis fungoides. Arch Dermatol. 2000;136:748\u201352. https:\/\/doi.org\/10.1001\/ARCHDERM.136.6.748.","journal-title":"Arch Dermatol"},{"key":"1511_CR45","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/J.JAAD.2011.04.004","volume":"66","author":"RS Stern","year":"2012","unstructured":"Stern RS. The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30-year prospective study. J Am Acad Dermatol. 2012;66:553\u201362. https:\/\/doi.org\/10.1016\/J.JAAD.2011.04.004.","journal-title":"J Am Acad Dermatol"},{"key":"1511_CR46","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1067\/MJD.2003.80","volume":"48","author":"PVMM Diederen","year":"2003","unstructured":"Diederen PVMM, Van Weelden H, Sanders CJG, et al. Narrowband UVB and psoralen-UVA in the treatment of early-stage mycosis fungoides: a retrospective study. J Am Acad Dermatol. 2003;48:215\u20139. https:\/\/doi.org\/10.1067\/MJD.2003.80.","journal-title":"J Am Acad Dermatol"},{"key":"1511_CR47","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1001\/ARCHDERM.138.3.325","volume":"138","author":"D Breneman","year":"2002","unstructured":"Breneman D, Duvic M, Kuzel T, et al. Phase\u00a01 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol. 2002;138:325\u201332. https:\/\/doi.org\/10.1001\/ARCHDERM.138.3.325.","journal-title":"Arch Dermatol"},{"key":"1511_CR48","doi-asserted-by":"publisher","DOI":"10.1111\/DTH.15418","volume":"35","author":"E Ginsburg","year":"2022","unstructured":"Ginsburg E, Hennessy K, Mhaskar R, Seminario-Vidal L. Treatment of early-stage mycosis fungoides with oral bexarotene and phototherapy: a systematic review and meta-analysis. Dermatol Ther. 2022;35:e15418. https:\/\/doi.org\/10.1111\/DTH.15418.","journal-title":"Dermatol Ther"},{"key":"1511_CR49","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008946.PUB3\/MEDIA\/CDSR\/CD008946\/URN:X-WILEY:14651858:MEDIA:CD008946:CD008946-CMP-007.03","author":"A Valipour","year":"2020","unstructured":"Valipour A, J\u00e4ger M, Wu P, et al. Interventions for mycosis fungoides. Cochrane Database Syst Rev. 2020. https:\/\/doi.org\/10.1002\/14651858.CD008946.PUB3\/MEDIA\/CDSR\/CD008946\/URN:X-WILEY:14651858:MEDIA:CD008946:CD008946-CMP-007.03.","journal-title":"Cochrane Database Syst Rev"},{"key":"1511_CR50","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/J.CTRV.2014.06.005","volume":"40","author":"D Humme","year":"2014","unstructured":"Humme D, Nast A, Erdmann R, et al. Systematic review of combination therapies for mycosis fungoides. Cancer Treat Rev. 2014;40:927\u201333. https:\/\/doi.org\/10.1016\/J.CTRV.2014.06.005.","journal-title":"Cancer Treat Rev"},{"key":"1511_CR51","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.biopha.2018.07.049","volume":"106","author":"S Kwiatkowski","year":"2018","unstructured":"Kwiatkowski S, Knap B, Przystupski D, et al. Photodynamic therapy \u2013 mechanisms, photosensitizers and combinations. Biomed Pharmacother. 2018;106:1098\u2013107. https:\/\/doi.org\/10.1016\/j.biopha.2018.07.049.","journal-title":"Biomed Pharmacother"},{"key":"1511_CR52","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2217\/fon.13.176","volume":"10","author":"RR Allison","year":"2014","unstructured":"Allison RR. Photodynamic therapy: oncologic horizons. Future Oncol. 2014;10:123\u20134. https:\/\/doi.org\/10.2217\/fon.13.176.","journal-title":"Future Oncol"},{"key":"1511_CR53","doi-asserted-by":"publisher","first-page":"188308","DOI":"10.1016\/j.bbcan.2019.07.003","volume":"1872","author":"C Donohoe","year":"2019","unstructured":"Donohoe C, Senge MO, Arnaut LG, Gomes-da-Silva LC. Cell death in photodynamic therapy: from oxidative stress to anti-tumor immunity. Biochim Biophys Acta Rev Cancer. 2019;1872:188308. https:\/\/doi.org\/10.1016\/j.bbcan.2019.07.003.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"1511_CR54","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3390\/pharmaceutics15010047","volume":"15","author":"S Caccavale","year":"2022","unstructured":"Caccavale S, Tancredi V, Vitiello P, et al. Photodynamic therapy as an effective treatment for cutaneous lymphomas. Pharmaceutics. 2022;15:47. https:\/\/doi.org\/10.3390\/pharmaceutics15010047.","journal-title":"Pharmaceutics"},{"key":"1511_CR55","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/phpp.12698","volume":"37","author":"M Hooper","year":"2021","unstructured":"Hooper M, Hatch L, Seminario-Vidal L. Photodynamic therapy of mycosis fungoides: a systematic review of case studies. Photodermatol Photoimmunol Photomed. 2021;37:549\u201352. https:\/\/doi.org\/10.1111\/phpp.12698.","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"1511_CR56","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1111\/j.1365-2133.1994.tb03412.x","volume":"130","author":"K Svanberg","year":"1994","unstructured":"Svanberg K, Andersson T, Killander D, et al. Photodynamic therapy of non-melanoma malignant tumours of the skin using topical \u03b4-amino levulinic acid sensitization and laser irradiation. Br J Dermatol. 1994;130:743\u201351. https:\/\/doi.org\/10.1111\/j.1365-2133.1994.tb03412.x.","journal-title":"Br J Dermatol"},{"key":"1511_CR57","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/j.1365-4632.2008.03177.x","volume":"47","author":"E D\u00edez Recio","year":"2008","unstructured":"D\u00edez Recio E, Zambrano B, Alonso ML, et al. Topical 5-aminolevulinic acid photodynamic therapy for the treatment of unilesional mycosis fungoides: a report of two cases and review of the literature. Int J Dermatol. 2008;47:410\u20133. https:\/\/doi.org\/10.1111\/j.1365-4632.2008.03177.x.","journal-title":"Int J Dermatol"},{"key":"1511_CR58","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1046\/j.1524-4725.2000.00056.x","volume":"26","author":"A Orenstein","year":"2000","unstructured":"Orenstein A, Haik J, Tamir J, et al. Photodynamic therapy of cutaneous lymphoma using 5-aminolevulinic acid topical application. Dermatol Surg. 2000;26:765\u201370. https:\/\/doi.org\/10.1046\/j.1524-4725.2000.00056.x.","journal-title":"Dermatol Surg"},{"key":"1511_CR59","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1080\/000155501750376276","volume":"81","author":"DW Edstr\u00f6m","year":"2001","unstructured":"Edstr\u00f6m DW, Porwit A, Ros AM. Photodynamic therapy with topical 5-aminolevulinic acid for mycosis fungoides: clinical and histological response. Acta Derm Venereol. 2001;81:184\u20138. https:\/\/doi.org\/10.1080\/000155501750376276.","journal-title":"Acta Derm Venereol"},{"key":"1511_CR60","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.pdpdt.2016.07.011","volume":"16","author":"D Han","year":"2016","unstructured":"Han D, Xue J, Wang T, Liu Y. Observation of clinical efficacy of photodynamic therapy in 3 patients with refractory plaque-stage mycosis fungoides. Photodiagnosis Photodyn Ther. 2016;16:9\u201311. https:\/\/doi.org\/10.1016\/j.pdpdt.2016.07.011.","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"1511_CR61","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1111\/j.1365-2230.2012.04352.x","volume":"37","author":"GW Mendese","year":"2012","unstructured":"Mendese GW, Beckford A, Krejci N, et al. Pagetoid reticulosis in a prepubescent boy successfully treated with photodynamic therapy. Clin Exp Dermatol. 2012;37:759\u201361. https:\/\/doi.org\/10.1111\/j.1365-2230.2012.04352.x.","journal-title":"Clin Exp Dermatol"},{"key":"1511_CR62","doi-asserted-by":"publisher","first-page":"112244","DOI":"10.1016\/j.jphotobiol.2021.112244","volume":"221","author":"P Vallecorsa","year":"2021","unstructured":"Vallecorsa P, Di Venosa G, Gola G, et al. Photodynamic therapy of cutaneous T-cell lymphoma cell lines mediated by 5-aminolevulinic acid and derivatives. J Photochem Photobiol B. 2021;221:112244. https:\/\/doi.org\/10.1016\/j.jphotobiol.2021.112244.","journal-title":"J Photochem Photobiol B"},{"key":"1511_CR63","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/j.1600-0781.2006.00246.x","volume":"22","author":"C Zane","year":"2006","unstructured":"Zane C, Venturini M, Sala R, Calzavara-Pinton P. Photodynamic therapy with methylaminolevulinate as a valuable treatment option for unilesional cutaneous T-cell lymphoma. Photodermatol Photoimmunol Photomed. 2006;22:254\u20138. https:\/\/doi.org\/10.1111\/j.1600-0781.2006.00246.x.","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"1511_CR64","doi-asserted-by":"publisher","first-page":"264","DOI":"10.2340\/00015555-1261","volume":"92","author":"S Kim","year":"2012","unstructured":"Kim S, Kang D, Kang J, et al. Photodynamic therapy with methyl-aminolaevulinic acid for mycosis fungoides. Acta Derm Venereol. 2012;92:264\u20138. https:\/\/doi.org\/10.2340\/00015555-1261.","journal-title":"Acta Derm Venereol"},{"key":"1511_CR65","first-page":"75","volume":"17","author":"J Hegyi","year":"2008","unstructured":"Hegyi J, Frey T, Arenberger P. Unilesional mycosis fungoides treated with photodynamic therapy. A case report. Acta Dermatoven APA. 2008;17:75.","journal-title":"Acta Dermatoven APA"},{"key":"1511_CR66","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1111\/j.1365-4632.2011.05427.x","volume":"52","author":"A Hasson","year":"2013","unstructured":"Hasson A, Navarrete-Dechent C, Nicklas C, Sazunic I. Topical photodynamic therapy with 5-aminolevulinate for the treatment of tumor-stage mycosis fungoides: a case report. Int J Dermatol. 2013;52:1535\u20137. https:\/\/doi.org\/10.1111\/j.1365-4632.2011.05427.x.","journal-title":"Int J Dermatol"},{"key":"1511_CR67","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.pdpdt.2017.09.004","volume":"20","author":"A Pileri","year":"2017","unstructured":"Pileri A, Sgubbi P, Agostinelli C, et al. Photodynamic therapy: an option in mycosis fungoides. Photodiagnosis Photodyn Ther. 2017;20:107\u201310. https:\/\/doi.org\/10.1016\/j.pdpdt.2017.09.004.","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"1511_CR68","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.jaad.2013.07.047","volume":"69","author":"G Qu\u00e9reux","year":"2013","unstructured":"Qu\u00e9reux G, Brocard A, Saint-Jean M, et al. Photodynamic therapy with methyl-aminolevulinic acid for paucilesional mycosis fungoides: a prospective open study and review of the literature. J Am Acad Dermatol. 2013;69:890\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2013.07.047.","journal-title":"J Am Acad Dermatol"},{"key":"1511_CR69","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2147\/CCID.S35334","volume":"7","author":"MT Wan","year":"2014","unstructured":"Wan MT, Lin JY. Current evidence and applications of photodynamic therapy in dermatology. Clin Cosmet Investig Dermatol. 2014;7:145\u201363. https:\/\/doi.org\/10.2147\/CCID.S35334.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"1511_CR70","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1001\/archderm.139.9.1173","volume":"139","author":"SR Wiegell","year":"2003","unstructured":"Wiegell SR. Pain associated with photodynamic therapy using 5-aminolevulinic acid or 5-aminolevulinic acid methylester on tape-stripped normal skin. Arch Dermatol. 2003;139:1173. https:\/\/doi.org\/10.1001\/archderm.139.9.1173.","journal-title":"Arch Dermatol"},{"key":"1511_CR71","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/j.1365-2133.2007.07946.x","volume":"157","author":"FJ Moloney","year":"2007","unstructured":"Moloney FJ, Collins P. Randomized, double-blind, prospective study to compare topical 5-aminolaevulinic acid methylester with topical 5-aminolaevulinic acid photodynamic therapy for extensive scalp actinic keratosis. Br J Dermatol. 2007;157:87\u201391. https:\/\/doi.org\/10.1111\/j.1365-2133.2007.07946.x.","journal-title":"Br J Dermatol"},{"key":"1511_CR72","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1111\/j.1346-8138.2005.tb00857.x","volume":"32","author":"S Yokoyama","year":"2005","unstructured":"Yokoyama S, Nakano H, Nishizawa A, et al. A case of photocontact urticaria induced by photodynamic therapy with topical 5-aminolaevulinic acid. J Dermatol. 2005;32:843\u20137. https:\/\/doi.org\/10.1111\/j.1346-8138.2005.tb00857.x.","journal-title":"J Dermatol"},{"key":"1511_CR73","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1001\/jamadermatol.2022.2749","volume":"158","author":"EJ Kim","year":"2022","unstructured":"Kim EJ, Mangold AR, DeSimone JA, et al. Efficacy and safety of topical hypericin photodynamic therapy for early-stage cutaneous T-cell lymphoma (mycosis fungoides). JAMA Dermatol. 2022;158:1031. https:\/\/doi.org\/10.1001\/jamadermatol.2022.2749.","journal-title":"JAMA Dermatol"},{"key":"1511_CR74","doi-asserted-by":"publisher","first-page":"104377","DOI":"10.1016\/j.pdpdt.2024.104377","volume":"50","author":"B Scotti","year":"2024","unstructured":"Scotti B, Piraccini BM, Pileri A. Folliculotropic mycosis fungoides of the face successfully treated combining CO2 laser and conventional photodynamic therapy (c-PDT). Photodiagnosis Photodyn Ther. 2024;50:104377. https:\/\/doi.org\/10.1016\/j.pdpdt.2024.104377.","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"1511_CR75","doi-asserted-by":"publisher","first-page":"10.1067\/MJD.200","DOI":"10.1067\/mjd.2000.107808","volume":"43","author":"DN Sauder","year":"2000","unstructured":"Sauder DN. Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol. 2000;43:10.1067\/MJD.2000.107808.","journal-title":"J Am Acad Dermatol"},{"key":"1511_CR76","doi-asserted-by":"publisher","first-page":"764557","DOI":"10.3389\/FIMMU.2022.764557\/FULL","volume":"13","author":"A Nomura","year":"2022","unstructured":"Nomura A, Mizuno M, Noto D, et al. Different spatial and temporal roles of monocytes and monocyte-derived cells in the pathogenesis of an Imiquimod induced lupus model. Front Immunol. 2022;13:764557. https:\/\/doi.org\/10.3389\/FIMMU.2022.764557\/FULL.","journal-title":"Front Immunol"},{"key":"1511_CR77","doi-asserted-by":"publisher","first-page":"119","DOI":"10.4103\/0019-5154.174085","volume":"61","author":"A Shipman","year":"2016","unstructured":"Shipman A, Scarisbrick J. New treatment options for mycosis fungoides. Indian J Dermatol. 2016;61:119. https:\/\/doi.org\/10.4103\/0019-5154.174085.","journal-title":"Indian J Dermatol"},{"key":"1511_CR78","doi-asserted-by":"publisher","first-page":"673","DOI":"10.4103\/IDOJ.IDOJ_446_23","volume":"15","author":"V Gaurav","year":"2023","unstructured":"Gaurav V, Mehta N, Gupta S. \u201cImmunopeeling\u201d using imiquimod for xeroderma pigmentosum. Indian Dermatol Online J. 2023;15:673. https:\/\/doi.org\/10.4103\/IDOJ.IDOJ_446_23.","journal-title":"Indian Dermatol Online J"},{"key":"1511_CR79","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/CCO.0000000000000048","volume":"26","author":"AO Huen","year":"2014","unstructured":"Huen AO, Rook AH. Toll receptor agonist therapy of skin cancer and cutaneous T-cell lymphoma. Curr Opin Oncol. 2014;26:237\u201344. https:\/\/doi.org\/10.1097\/CCO.0000000000000048.","journal-title":"Curr Opin Oncol"},{"key":"1511_CR80","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/J.JAAD.2020.12.026","volume":"84","author":"DM Weiner","year":"2021","unstructured":"Weiner DM, Durgin JS, Wysocka M, Rook AH. The immunopathogenesis and immunotherapy of cutaneous T\u00a0cell lymphoma: current and future approaches. J Am Acad Dermatol. 2021;84:597\u2013604. https:\/\/doi.org\/10.1016\/J.JAAD.2020.12.026.","journal-title":"J Am Acad Dermatol"},{"key":"1511_CR81","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/S11899-017-0387-9","volume":"12","author":"S Berg","year":"2017","unstructured":"Berg S, Villasenor-Park J, Haun P, Kim EJ. Multidisciplinary management of mycosis fungoides\/S\u00e9zary syndrome. Curr Hematol Malig Rep. 2017;12:234\u201343. https:\/\/doi.org\/10.1007\/S11899-017-0387-9.","journal-title":"Curr Hematol Malig Rep"},{"key":"1511_CR82","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1182\/BLOOD-2015-02-630335","volume":"126","author":"AH Rook","year":"2015","unstructured":"Rook AH, Gelfand JM, Wysocka M, et al. Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma. Blood. 2015;126:1452\u201361. https:\/\/doi.org\/10.1182\/BLOOD-2015-02-630335.","journal-title":"Blood"},{"key":"1511_CR83","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1080\/13543784.2019.1654995","volume":"28","author":"E Ramelyte","year":"2019","unstructured":"Ramelyte E, Dummer R, Guenova E. Investigative drugs for the treatment of cutaneous T-cell lymphomas (CTCL): an update. Expert Opin Investig Drugs. 2019;28:799\u2013809. https:\/\/doi.org\/10.1080\/13543784.2019.1654995.","journal-title":"Expert Opin Investig Drugs"},{"key":"1511_CR84","doi-asserted-by":"publisher","first-page":"228","DOI":"10.2310\/7750.2006.00051","volume":"10","author":"A Freiman","year":"2006","unstructured":"Freiman A, Sasseville D. Treatment of mycosis fungoides: overview. J Cutan Med Surg. 2006;10:228\u201333. https:\/\/doi.org\/10.2310\/7750.2006.00051.","journal-title":"J Cutan Med Surg"},{"key":"1511_CR85","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/S13555-019-00317-2","volume":"9","author":"D Shalabi","year":"2019","unstructured":"Shalabi D, Vadalia N, Nikbakht N. Revisiting imiquimod for treatment of folliculotropic mycosis fungoides: a case report and review of the literature. Dermatol Ther (Heidelb). 2019;9:807\u201314. https:\/\/doi.org\/10.1007\/S13555-019-00317-2.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1511_CR86","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1080\/09546634.2017.1294728","volume":"28","author":"DJ Lewis","year":"2017","unstructured":"Lewis DJ, Byekova YA, Emge DA, Duvic M. Complete resolution of mycosis fungoides tumors with imiquimod 5% cream: a case series. J Dermatolog Treat. 2017;28:567\u20139. https:\/\/doi.org\/10.1080\/09546634.2017.1294728.","journal-title":"J Dermatolog Treat"},{"key":"1511_CR87","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/J.JDCR.2015.08.007","volume":"1","author":"MC Gordon","year":"2015","unstructured":"Gordon MC, Sluzevich JC, Jambusaria-Pahlajani A. Clearance of folliculotropic and tumor mycosis fungoides with topical 5% imiquimod. JAAD Case Rep. 2015;1:348. https:\/\/doi.org\/10.1016\/J.JDCR.2015.08.007.","journal-title":"JAAD Case Rep"},{"key":"1511_CR88","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1111\/J.1365-2133.2006.07599.X","volume":"156","author":"LYT Chiam","year":"2007","unstructured":"Chiam LYT, Chan YC. Solitary plaque mycosis fungoides on the penis responding to topical imiquimod therapy. Br J Dermatol. 2007;156:560\u20132. https:\/\/doi.org\/10.1111\/J.1365-2133.2006.07599.X.","journal-title":"Br J Dermatol"},{"key":"1511_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/J.EUCR.2020.101460","volume":"34","author":"C Schaufler","year":"2020","unstructured":"Schaufler C, Ferenczi K, Hegde U, Ristau BT. Complete response of penile mycosis fungoides with systemic brentuximab therapy. Urol Case Rep. 2020;34:101460. https:\/\/doi.org\/10.1016\/J.EUCR.2020.101460.","journal-title":"Urol Case Rep"},{"key":"1511_CR90","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1080\/09546630310019373","volume":"15","author":"A Chong","year":"2004","unstructured":"Chong A, Loo WJ, Banney L, et al. Imiquimod 5% cream in the treatment of mycosis fungoides\u2013a pilot study. J Dermatolog Treat. 2004;15:118\u20139. https:\/\/doi.org\/10.1080\/09546630310019373.","journal-title":"J Dermatolog Treat"},{"key":"1511_CR91","first-page":"E79","volume":"62","author":"H Mori","year":"2016","unstructured":"Mori H, Arita K, Yamaguchi T, et al. Effects of topical application of betamethasone on imiquimod-induced psoriasis-like skin inflammation in mice. Kobe J Med Sci. 2016;62:E79.","journal-title":"Kobe J Med Sci"},{"key":"1511_CR92","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1517\/13543784.2013.749236","volume":"22","author":"T Meyer","year":"2013","unstructured":"Meyer T, Surber C, French LE, Stockfleth E. Resiquimod, a topical drug for viral skin lesions and skin cancer. Expert Opin Investig Drugs. 2013;22:149\u201359. https:\/\/doi.org\/10.1517\/13543784.2013.749236.","journal-title":"Expert Opin Investig Drugs"},{"key":"1511_CR93","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1093\/JNCI\/DJI207","volume":"97","author":"M Urosevic","year":"2005","unstructured":"Urosevic M, Dummer R, Conrad C, et al. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. J Natl Cancer Inst. 2005;97:1143\u201353. https:\/\/doi.org\/10.1093\/JNCI\/DJI207.","journal-title":"J Natl Cancer Inst"},{"key":"1511_CR94","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.2165\/00003495-200767150-00006","volume":"67","author":"AJ Wagstaff","year":"2007","unstructured":"Wagstaff AJ, Perry CM. Topical imiquimod: a review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma and other skin lesions. Drugs. 2007;67:2187\u2013210. https:\/\/doi.org\/10.2165\/00003495-200767150-00006.","journal-title":"Drugs"},{"key":"1511_CR95","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1093\/NAR\/GKAD1178","volume":"52","author":"I Torrecilla","year":"2024","unstructured":"Torrecilla I, Ruggiano A, Kiianitsa K, et al. Isolation and detection of DNA\u2013protein crosslinks in mammalian cells. Nucleic Acids Res. 2024;52:525\u201347. https:\/\/doi.org\/10.1093\/NAR\/GKAD1178.","journal-title":"Nucleic Acids Res"},{"key":"1511_CR96","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1021\/PR200042U","volume":"10","author":"ED Michaelson-Richie","year":"2011","unstructured":"Michaelson-Richie ED, Ming X, Codreanu SG, et al. Mechlorethamine-induced DNA-protein cross-linking in human fibrosarcoma (HT1080) cells. J Proteome Res. 2011;10:2785\u201396. https:\/\/doi.org\/10.1021\/PR200042U.","journal-title":"J Proteome Res"},{"key":"1511_CR97","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1111\/JDV.19237","volume":"37","author":"E Guenova","year":"2023","unstructured":"Guenova E, Ortiz-Romero PL, Poligone B, Querfeld C. Mechanism of action of chlormethine gel in mycosis fungoides. J Eur Acad Dermatol Venereol. 2023;37:1739\u201348. https:\/\/doi.org\/10.1111\/JDV.19237.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1511_CR98","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1586\/17512433.2014.944500","volume":"7","author":"R Talpur","year":"2014","unstructured":"Talpur R, Venkatarajan S, Duvic M. Mechlorethamine gel for the topical treatment of stage\u00a0IA and IB mycosis fungoides-type cutaneous T-cell lymphoma. Expert Rev Clin Pharmacol. 2014;7:591\u20137. https:\/\/doi.org\/10.1586\/17512433.2014.944500.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1511_CR99","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/2013.JAMADERMATOL.541","volume":"149","author":"SR Lessin","year":"2013","unstructured":"Lessin SR, Duvic M, Guitart J, et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol. 2013;149:25\u201332. https:\/\/doi.org\/10.1001\/2013.JAMADERMATOL.541.","journal-title":"JAMA Dermatol"},{"key":"1511_CR100","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/ARCHDERM.139.2.165","volume":"139","author":"YH Kim","year":"2003","unstructured":"Kim YH, Martinez G, Varghese A, Hoppe RT. Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience. Arch Dermatol. 2003;139:165\u201373. https:\/\/doi.org\/10.1001\/ARCHDERM.139.2.165.","journal-title":"Arch Dermatol"},{"key":"1511_CR101","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/S40257-021-00591-X","volume":"22","author":"EJ Kim","year":"2021","unstructured":"Kim EJ, Guitart J, Querfeld C, et al. The PROVe study: US real-world experience with chlormethine\/mechlorethamine gel in combination with other therapies for patients with mycosis fungoides cutaneous T-cell lymphoma. Am J Clin Dermatol. 2021;22:407\u201314. https:\/\/doi.org\/10.1007\/S40257-021-00591-X.","journal-title":"Am J Clin Dermatol"},{"key":"1511_CR102","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1159\/000516138","volume":"238","author":"C Querfeld","year":"2022","unstructured":"Querfeld C, Scarisbrick JJ, Assaf C, et al. Post hoc analysis of a randomized, controlled, phase\u00a02 study to assess response rates with chlormethine\/mechlorethamine gel in patients with stage\u00a0IA-IIA mycosis fungoides. Dermatology. 2022;238:347\u201357. https:\/\/doi.org\/10.1159\/000516138.","journal-title":"Dermatology"},{"key":"1511_CR103","doi-asserted-by":"publisher","first-page":"474","DOI":"10.5021\/AD.2011.23.4.474","volume":"23","author":"MS Jang","year":"2011","unstructured":"Jang MS, Baek JW, Park JB, et al. Narrowband ultraviolet B phototherapy of early stage mycosis fungoides in Korean patients. Ann Dermatol. 2011;23:474. https:\/\/doi.org\/10.5021\/AD.2011.23.4.474.","journal-title":"Ann Dermatol"},{"key":"1511_CR104","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.2147\/CMAR.S351420","volume":"14","author":"C Crimp","year":"2022","unstructured":"Crimp C, Gangal A, Tarabadkar ES, Shinohara MM. Mechlorethamine hydrochloride gel in the treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL): a focus on patient selection and special considerations. Cancer Manag Res. 2022;14:3271\u20139. https:\/\/doi.org\/10.2147\/CMAR.S351420.","journal-title":"Cancer Manag Res"},{"key":"1511_CR105","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/S13555-022-00681-6","volume":"12","author":"CV Alexander-Savino","year":"2022","unstructured":"Alexander-Savino CV, Chung CG, Gilmore ES, et al. Randomized mechlorethamine\/chlormethine induced dermatitis assessment study (MIDAS) establishes benefit of topical triamcinolone 0.1% ointment cotreatment in mycosis fungoides. Dermatol Ther (Heidelb). 2022;12:643\u201354. https:\/\/doi.org\/10.1007\/S13555-022-00681-6.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1511_CR106","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/S11224-020-01604-X","volume":"32","author":"SHDM Faria","year":"2021","unstructured":"Faria SHDM, Teleschi JG, Teodoro L, Almeida MO. Computational investigation of the carmustine (BCNU) alkylation mechanism using the QTAIM, IQA, and NBO models. Struct Chem. 2021;32:79\u201396. https:\/\/doi.org\/10.1007\/S11224-020-01604-X.","journal-title":"Struct Chem"},{"issue":"16","key":"1511_CR107","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.3390\/CANCERS16183123","volume":"2024","author":"CMC Andr\u00e9s","year":"2024","unstructured":"Andr\u00e9s CMC, P\u00e9rez de la Lastra JM, Munguira EB, et al. Dual-action therapeutics: DNA alkylation and antimicrobial peptides for cancer therapy. Cancers. 2024;2024(16):3123. https:\/\/doi.org\/10.3390\/CANCERS16183123.","journal-title":"Cancers"},{"key":"1511_CR108","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1001\/JAMADERMATOL.2016.5793","volume":"153","author":"JD Tacastacas","year":"2017","unstructured":"Tacastacas JD, Chan DV, Carlson S, et al. Evaluation of O6-benzylguanine-potentiated topical carmustine for mycosis fungoides: a phase\u00a01\u20132 clinical trial. JAMA Dermatol. 2017;153:413\u201320. https:\/\/doi.org\/10.1001\/JAMADERMATOL.2016.5793.","journal-title":"JAMA Dermatol"},{"key":"1511_CR109","first-page":"491","volume":"24","author":"S Galper","year":"2010","unstructured":"Galper S, Smith B, Wilson L. Diagnosis and management of mycosis fungoides. Oncology (Williston Park). 2010;24:491\u2013501.","journal-title":"Oncology (Williston Park)"},{"key":"1511_CR110","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/ARCHDERMATOL.2011.98","volume":"147","author":"D Navi","year":"2011","unstructured":"Navi D, Riaz N, Levin YS, et al. The Stanford University experience with conventional-dose, total skin electron-beam therapy in the treatment of generalized patch or plaque (T2) and tumor (T3) mycosis fungoides. Arch Dermatol. 2011;147:561\u20137. https:\/\/doi.org\/10.1001\/ARCHDERMATOL.2011.98.","journal-title":"Arch Dermatol"},{"key":"1511_CR111","doi-asserted-by":"publisher","first-page":"9","DOI":"10.21037\/CCO.2018.09.02","volume":"8","author":"M Chowdhary","year":"2019","unstructured":"Chowdhary M, Song A, Zaorsky NG, Shi W. Total skin electron beam therapy in mycosis fungoides\u2014a shift towards lower dose? Chin Clin Oncol. 2019;8:9\u20139. https:\/\/doi.org\/10.21037\/CCO.2018.09.02.","journal-title":"Chin Clin Oncol"},{"key":"1511_CR112","doi-asserted-by":"publisher","first-page":"852345","DOI":"10.3389\/FONC.2022.852345","volume":"12","author":"H Wang","year":"2022","unstructured":"Wang H, Pi Y, Guo Y, et al. Influencing factors of total skin irradiation with helical tomotherapy. Front Oncol. 2022;12:852345. https:\/\/doi.org\/10.3389\/FONC.2022.852345.","journal-title":"Front Oncol"},{"key":"1511_CR113","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13014-018-1013-2\/TABLES\/2","volume":"13","author":"EM Schaff","year":"2018","unstructured":"Schaff EM, Rosenberg SA, Olson SJ, et al. Bone marrow suppression as a complication of total skin helical tomotherapy in the treatment of mycosis fungoides. Radiat Oncol. 2018;13:1\u20135. https:\/\/doi.org\/10.1186\/S13014-018-1013-2\/TABLES\/2.","journal-title":"Radiat Oncol"},{"key":"1511_CR114","doi-asserted-by":"publisher","first-page":"e308","DOI":"10.1016\/j.prro.2020.11.007","volume":"11","author":"M Kitaguchi","year":"2021","unstructured":"Kitaguchi M, Yamashita H, Takenaka R, et al. Helical skin radiation therapy including total skin radiation therapy using tomotherapy for primary cutaneous lymphoma with bone marrow suppression as a related adverse event. Pract Radiat Oncol. 2021;11:e308\u201321. https:\/\/doi.org\/10.1016\/j.prro.2020.11.007.","journal-title":"Pract Radiat Oncol"},{"key":"1511_CR115","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/J.1749-6632.2001.TB03723.X","volume":"941","author":"BM Kacinski","year":"2001","unstructured":"Kacinski BM, Flick M. Apoptosis and cutaneous T\u00a0cell lymphoma. Ann N Y Acad Sci. 2001;941:194\u20139. https:\/\/doi.org\/10.1111\/J.1749-6632.2001.TB03723.X.","journal-title":"Ann N Y Acad Sci"},{"key":"1511_CR116","doi-asserted-by":"publisher","DOI":"10.7759\/CUREUS.43959","author":"F Kouhen","year":"2023","unstructured":"Kouhen F, Oqbani K, El Gouach H, et al. Overcoming chemotherapy resistance in cutaneous T-cell lymphoma: a successful case of high-dose radiotherapy management. Cureus. 2023. https:\/\/doi.org\/10.7759\/CUREUS.43959.","journal-title":"Cureus"},{"key":"1511_CR117","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ejmp.2010.09.001","volume":"27","author":"S Diamantopoulos","year":"2011","unstructured":"Diamantopoulos S, Platoni K, Dilvoi M, et al. Clinical implementation of total skin electron beam (TSEB) therapy: a review of the relevant literature. Phys Med. 2011;27:62\u20138. https:\/\/doi.org\/10.1016\/j.ejmp.2010.09.001.","journal-title":"Phys Med"},{"key":"1511_CR118","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/J.ANNDER.2022.02.006","volume":"149","author":"D Canu","year":"2022","unstructured":"Canu D, Pham-Ledard A, Ouhabrache N, Beylot-Barry M. Changes in total skin electron beam therapy modalities for mycosis fungoides: a single-centre study. Ann Dermatol Venereol. 2022;149:180\u20134. https:\/\/doi.org\/10.1016\/J.ANNDER.2022.02.006.","journal-title":"Ann Dermatol Venereol"},{"key":"1511_CR119","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/0360-3016(94)90103-1","volume":"28","author":"GW Jones","year":"1994","unstructured":"Jones GW, Tadros A, Hodson DI, et al. Prognosis with newly diagnosed mycosis fungoides after total skin electron radiation of 30 or 35 GY. Int J Radiat Oncol Biol Phys. 1994;28:839\u201345. https:\/\/doi.org\/10.1016\/0360-3016(94)90103-1.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1511_CR120","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/4216098","author":"\u0130P Aral","year":"2020","unstructured":"Aral \u0130P, G\u00f6\u00e7er G\u00fcrok N, Konuk AO, \u00dc\u00e7er \u00d6. Ultra-low-dose radiotherapy for palliation of mycosis fungoides. Case Rep Dermatol Med. 2020. https:\/\/doi.org\/10.1155\/2020\/4216098.","journal-title":"Case Rep Dermatol Med"},{"key":"1511_CR121","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1080\/10428194.2023.2254435","volume":"64","author":"J Pena","year":"2023","unstructured":"Pena J, Cull D, Strowd LC, et al. Response and local control in patients treated with low-dose radiotherapy for tumoral mycosis fungoides. Leuk Lymphoma. 2023;64:2202\u20137. https:\/\/doi.org\/10.1080\/10428194.2023.2254435.","journal-title":"Leuk Lymphoma"},{"key":"1511_CR122","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/J.CTRO.2021.12.001","volume":"33","author":"K Smits","year":"2022","unstructured":"Smits K, Quint KD, Vermeer MH, et al. Total skin electron beam therapy for cutaneous T-cell lymphomas in the Netherlands: a retrospective analysis of treatment outcomes and selection for high or low dose schedule. Clin Transl Radiat Oncol. 2022;33:77\u201382. https:\/\/doi.org\/10.1016\/J.CTRO.2021.12.001.","journal-title":"Clin Transl Radiat Oncol"},{"key":"1511_CR123","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ijrobp.2023.02.052","volume":"117","author":"K Elsayad","year":"2023","unstructured":"Elsayad K, Weishaupt C, Moustakis C, et al. Ultrahypofractionated low-dose total skin electron beam in advanced-stage mycosis fungoides and S\u00e9zary syndrome. Int J Radiat Oncol Biol Phys. 2023;117:164\u201370. https:\/\/doi.org\/10.1016\/j.ijrobp.2023.02.052.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1511_CR124","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1159\/000475634","volume":"40","author":"K Elsayad","year":"2017","unstructured":"Elsayad K, Susek KH, Eich HT. Total skin electron beam therapy as part of multimodal treatment strategies for primary cutaneous T-cell lymphoma. Oncol Res Treat. 2017;40:244\u201352. https:\/\/doi.org\/10.1159\/000475634.","journal-title":"Oncol Res Treat"},{"key":"1511_CR125","doi-asserted-by":"publisher","first-page":"e15840","DOI":"10.1111\/DTH.15840","volume":"35","author":"V Grandi","year":"2022","unstructured":"Grandi V, Simontacchi G, Grassi T, et al. Short-term efficacy and safety of total skin electron beam therapy in mycosis fungoides: systematic review and meta-analysis. Dermatol Ther. 2022;35:e15840. https:\/\/doi.org\/10.1111\/DTH.15840.","journal-title":"Dermatol Ther"},{"key":"1511_CR126","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1001\/ARCHDERM.1995.01690160060009","volume":"131","author":"AG Licata","year":"1995","unstructured":"Licata AG, Wilson LD, Braverman IM, et al. Malignant melanoma and other second cutaneous malignancies in cutaneous T-cell lymphoma: the influence of additional therapy after total skin electron beam radiation. Arch Dermatol. 1995;131:432\u20135. https:\/\/doi.org\/10.1001\/ARCHDERM.1995.01690160060009.","journal-title":"Arch Dermatol"},{"key":"1511_CR127","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.clon.2018.06.006","volume":"30","author":"M Lutsyk","year":"2018","unstructured":"Lutsyk M, Ben-Yosef R, Bergman R, et al. Total skin electron irradiation and sequential malignancies in mycosis fungoides patients: longitudinal study. Clin Oncol. 2018;30:618\u201324. https:\/\/doi.org\/10.1016\/j.clon.2018.06.006.","journal-title":"Clin Oncol"},{"key":"1511_CR128","doi-asserted-by":"publisher","first-page":"15618","DOI":"10.1038\/NCOMMS15618","volume":"8","author":"C Vanpouille-Box","year":"2017","unstructured":"Vanpouille-Box C, Alard A, Aryankalayil MJ, et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun. 2017;8:15618. https:\/\/doi.org\/10.1038\/NCOMMS15618.","journal-title":"Nat Commun"},{"key":"1511_CR129","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/J.IMMUNI.2014.10.019","volume":"41","author":"L Deng","year":"2014","unstructured":"Deng L, Liang H, Xu M, et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type\u00a0I interferon-dependent antitumor immunity in immunogenic tumors. Immunity. 2014;41:843. https:\/\/doi.org\/10.1016\/J.IMMUNI.2014.10.019.","journal-title":"Immunity"},{"key":"1511_CR130","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3390\/CANCERS14010221\/S1","volume":"14","author":"HB Barsoumian","year":"2022","unstructured":"Barsoumian HB, Sezen D, Menon H, et al. High plus low dose radiation strategy in combination with TIGIT and PD1 blockade to promote systemic antitumor responses. Cancers (Basel). 2022;14:221. https:\/\/doi.org\/10.3390\/CANCERS14010221\/S1.","journal-title":"Cancers (Basel)"},{"key":"1511_CR131","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/NATURE23470","volume":"548","author":"SM Harding","year":"2017","unstructured":"Harding SM, Benci JL, Irianto J, et al. Mitotic progression following DNA damage enables pattern recognition within micronuclei. Nature. 2017;548:466\u201370. https:\/\/doi.org\/10.1038\/NATURE23470.","journal-title":"Nature"},{"key":"1511_CR132","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/J.CELL.2008.06.032\/ATTACHMENT\/3D1B81B5-3BAC-4034-A470-7EE079A86872\/MMC2.XLS","volume":"134","author":"DB Stetson","year":"2008","unstructured":"Stetson DB, Ko JS, Heidmann T, Medzhitov R. Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell. 2008;134:587\u201398. https:\/\/doi.org\/10.1016\/J.CELL.2008.06.032\/ATTACHMENT\/3D1B81B5-3BAC-4034-A470-7EE079A86872\/MMC2.XLS.","journal-title":"Cell"},{"key":"1511_CR133","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S0167-8140(99)00050-X","volume":"51","author":"YM Kirova","year":"1999","unstructured":"Kirova YM, Piedbois Y, Haddad E, et al. Radiotherapy in the management of mycosis fungoides: indications, results, prognosis. Twenty years experience. Radiother Oncol. 1999;51:147\u201351. https:\/\/doi.org\/10.1016\/S0167-8140(99)00050-X.","journal-title":"Radiother Oncol"},{"key":"1511_CR134","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.det.2015.05.006","volume":"33","author":"DJ Tandberg","year":"2015","unstructured":"Tandberg DJ, Craciunescu O, Kelsey CR. Radiation therapy for cutaneous T-cell lymphomas. Dermatol Clin. 2015;33:703\u201313. https:\/\/doi.org\/10.1016\/j.det.2015.05.006.","journal-title":"Dermatol Clin"},{"key":"1511_CR135","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1080\/09546630802516571","volume":"20","author":"R Piccinno","year":"2009","unstructured":"Piccinno R, Caccialanza M, Percivalle S. Minimal stage\u00a0IA mycosis fungoides. Results of radiotherapy in 15 patients. J Dermatolog Treat. 2009;20:165\u20138. https:\/\/doi.org\/10.1080\/09546630802516571.","journal-title":"J Dermatolog Treat"},{"key":"1511_CR136","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ijrobp.2008.06.1918","volume":"74","author":"KJ Neelis","year":"2009","unstructured":"Neelis KJ, Schimmel EC, Vermeer MH, et al. Low-dose palliative radiotherapy for cutaneous B- and T-cell lymphomas. Int J Radiat Oncol Biol Phys. 2009;74:154\u20138. https:\/\/doi.org\/10.1016\/j.ijrobp.2008.06.1918.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1511_CR137","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S0360-3016(98)00218-1","volume":"42","author":"B Micaily","year":"1998","unstructured":"Micaily B, Miyamoto C, Kantor G, et al. Radiotherapy for unilesional mycosis fungoides. Int J Radiat Oncol Biol Phys. 1998;42:361\u20134. https:\/\/doi.org\/10.1016\/S0360-3016(98)00218-1.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1511_CR138","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/J.JAAD.2012.02.039","volume":"67","author":"MS Ally","year":"2012","unstructured":"Ally MS, Pawade J, Tanaka M, et al. Solitary mycosis fungoides: a distinct clinicopathologic entity with a good prognosis: a series of 15 cases and literature review. J Am Acad Dermatol. 2012;67:736\u201344. https:\/\/doi.org\/10.1016\/J.JAAD.2012.02.039.","journal-title":"J Am Acad Dermatol"},{"key":"1511_CR139","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1111\/DDG.14462","volume":"19","author":"U Wehkamp","year":"2021","unstructured":"Wehkamp U, Jost M, Gosmann J, et al. Management of chlormethine gel treatment in mycosis fungoides patients in two German skin lymphoma centers. J Dtsch Dermatol Ges. 2021;19:1057\u20139. https:\/\/doi.org\/10.1111\/DDG.14462.","journal-title":"J Dtsch Dermatol Ges"},{"key":"1511_CR140","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1111\/JDV.18183","volume":"36","author":"E Papadavid","year":"2022","unstructured":"Papadavid E, Koumourtzis M, Nikolaou V, et al. Chlormethine gel is effective for the treatment of skin lesions in patients with early- and late-stage mycosis fungoides in clinical practice. J Eur Acad Dermatol Venereol. 2022;36:1751\u20137. https:\/\/doi.org\/10.1111\/JDV.18183.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1511_CR141","doi-asserted-by":"publisher","first-page":"373","DOI":"10.2340\/00015555-2551","volume":"97","author":"KM Macarthur","year":"2017","unstructured":"Macarthur KM, Jariwala N, Kim EJ, Rook AH. Topical carmustine as monotherapy or as multimodality therapy for folliculotropic mycosis fungoides. Acta Derm Venereol. 2017;97:373. https:\/\/doi.org\/10.2340\/00015555-2551.","journal-title":"Acta Derm Venereol"},{"key":"1511_CR142","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/J.1396-0296.2003.01641.X","volume":"16","author":"HS Zackheim","year":"2003","unstructured":"Zackheim HS. Topical carmustine (BCNU) in the treatment of mycosis fungoides. Dermatol Ther. 2003;16:299\u2013302. https:\/\/doi.org\/10.1111\/J.1396-0296.2003.01641.X.","journal-title":"Dermatol Ther"},{"key":"1511_CR143","doi-asserted-by":"publisher","first-page":"AB96","DOI":"10.1016\/j.jaad.2009.11.651","volume":"62","author":"D Santiago-et-Sanchez-Mateos","year":"2010","unstructured":"Santiago-et-Sanchez-Mateos D, Juarez A, Garcia-Diez A, et al. Topical carmustine in the treatment of mycosis fungoides: efficacy and side effects. J Am Acad Dermatol. 2010;62:AB96. https:\/\/doi.org\/10.1016\/j.jaad.2009.11.651.","journal-title":"J Am Acad Dermatol"},{"key":"1511_CR144","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/S0190-9622(83)70143-X","volume":"9","author":"HS Zackheim","year":"1983","unstructured":"Zackheim HS, Epstein EH, McNutt NS, et al. Topical carmustine (BCNU) for mycosis fungoides and related disorders: a 10-year experience. J Am Acad Dermatol. 1983;9:363\u201374. https:\/\/doi.org\/10.1016\/S0190-9622(83)70143-X.","journal-title":"J Am Acad Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01511-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01511-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01511-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T13:07:17Z","timestamp":1758719237000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01511-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":144,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1511"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01511-1","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,14]]},"assertion":[{"value":"14 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Layout of Table 3 updated","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Maciej Tota has nothing to disclose. Magdalena \u0141yko has nothing to disclose. Piotr Misi\u0105g has nothing to disclose. Julia \u0141acwik has nothing to disclose. Julia Laska has nothing to disclose. Karol Bili\u0144ski has nothing to disclose. Julita Kulbacka has nothing to disclose. Alina Jankowska-Konsur has nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}